Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Ascierto, Paolo A ^a   Grimaldi, Antonio M ^a   Anderson, Ana Carrizosa ^b   Bifulco, Carlo ^c   Cochran, Alistair ^d   Garbe, Claus ^e   Eggermont, Alexander M ^f   Faries, Mark ^g   Ferrone, Soldano ^h   Gershenwald, Jeffrey E ⁱ   Gajewski, Thomas F ^j   Halaban, Ruth ^k   Stephen Hodi, F ^l   Kefford, Richard ^m   Kirkwood, John M ⁿ   Larkin, James ^o   Leachman, Sancy ^p   Maio, Michele ^q   Marais, Richard ^r   Masucci, Giuseppe ^s   Melero, Ignacio ^t   Palmieri, Giuseppe ^u   Puzanov, Igor ^v   Ribas, Antoni ^w   Saenger, Yvonne ^x   Schilling, Bastian ^y,ae   Seliger, Barbara ^z   Stroncek, David ^aa   Sullivan, Ryan ^b   Testori, Alessandro ^ab   Wang, Ena ^ac   Ciliberto, Gennaro ^a   Mozzillo, Nicola ^a   Marincola, Francesco M ^ac   Thurin, Magdalena ^ad   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c EARLE A CHILES RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g JOHN WAYNE CANCER INSTITUTE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^o INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^p OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^q UNIVERSITY HOSPITAL OF SIENA   (Italy)

^r UNIVERSITY OF MANCHESTER   (United Kingdom)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t UNIVERSITY OF NAVARRA   (Spain)

^u CNR   (Italy)

^v VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^y UNIVERSITY HOSPITAL ESSEN   (Germany)

^z MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^aa NATIONAL INSTITUTES OF HEALTH   (United States)

^ab EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ac SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^ad NATIONAL CANCER INSTITUTE   (United States)

^ae GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BINIMETINIB; COBIMETINIB; CREATINE KINASE; DABRAFENIB; DACARBAZINE; ENCORAFENIB; EVEROLIMUS; GSK 2141795B; INTERLEUKIN 2; IPILIMUMAB; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PLACEBO; PLX 3397; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SELUMETINIB; SEPANTRONIUM BROMIDE; SERDEMETAN; TEMSIROLIMUS; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UPROSERTIB; VEMURAFENIB; VENETOCLAX; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER STAGING; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ELECTROCHEMOTHERAPY; EPILUMINESCENCE MICROSCOPY; EYE TOXICITY; FOLLOW UP; GASTROINTESTINAL DISEASE; GENE EXPRESSION MICROARRAY; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; HYPERTRANSAMINASEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DISEASE; LIVER TOXICITY; MELANOMA; METASTATIC MELANOMA; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAPULOPUSTOLAR CUTANEOUS RASH; PHYSICAL EXAMINATION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RASH; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE BIOPSY; SKIN DISEASE; SKIN EXAMINATION; SURVIVAL RATE; THERAPY RESISTANCE; TUMOR MICROENVIRONMENT; VISUAL DISORDER; IMMUNOTHERAPY; ITALY; METABOLISM; PATHOLOGY;

HUMANS; IMMUNOTHERAPY; ITALY; MELANOMA;

EID: 84988660611     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0277-z     Document Type: Article

References (124)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
3. Liebmann C: Regulation of MAP kinase activity by peptide receptor signaling pathway: paradigms of multiplicity. Cell Signal 2001, 13:777-785.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
5. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to thebrain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
6. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, et al: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105:3041-3046.
7. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N: BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
8. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG: Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006, 126:154-160.
9. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
10. McArthur G, Gonzalez R, Pavlick A, Hamid O, Puzanov I, Gajewski TF, Daud A, Yin M, Choong N, Ribas A: Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC0973), in advanced BRAF V600-mutated mela-noma (BRIM-7): dose-escalation and expansion results of a phase Ib study [abstract]. Eur J Cancer 2013, 49(Suppl. 2). abstract 3703.
11. Kefford R, Miller WH, Shao-Weng Tan D, Sullivan RJ, Long G, Dienstmann R, Tai WM, Flaherty K, Stutvoet S, Schumacher KM, Wandel S, De Parseval LA, Tabernero J: Preliminary results from a phase Ib/II, open-label, doseescalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J Clin Oncol 2013, 31(Suppl). abstract 9029.
12. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Janis M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
13. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
14. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
15. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: Safety and activity of anti-PD-L1 antibody in patients with cancer. N Engl J Med 2012, 366:2455-2465.
16. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, Boasberg PD, Flaherty K, Hwu P, Ballinger M, Mokatrin A, Kowanetz M, Chen DS, Hodi FS: Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (MM) [abstract]. J Clin Oncol 2013, 31(suppl). abstr 9010.
17. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, et al: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014, 20:2457-2465.
18. Phan GQ, Rosenberg SA: Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013, 20:289-297.
19. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA, Melanoma Genetics Consortium: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002, 94:894-903.
20. Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, Leachman SA: CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 2008, 17:1510-1519.
21. Aspinwall LG, Leaf SL, Kohlmann W, Dola ER, Leachman SA: Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol 2009, 60(5):745-757.
22. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA: Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev 2013, 22:1687-1697.
23. Blum A, Schlagenhauff B, Stroebel W, Breuninger H, Rassner G, Garbe C: Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. Cancer 2000, 88:2534-2539.
24. Weide B, Elsässer M, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Witte M, Meier F, Garbe C: Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 2012, 107:422-428.
25. Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003, 21:520-529.
26. Koh SS, Opel ML, Wei JP, Yau K, Shah R, Gorre ME, Whitman E, Shitabata PK, Tao Y, Cochran AJ, Abrishami P, Binder SW: Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue. Mod Pathol 2009, 22:538-546.
27. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK: Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009, 27:6199-6206.
28. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK: Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011, 29:2199-2205.
29. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK: Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 2013, 20:3961-3968.
30. Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC Jr, Morton DL, Atkins MB, Flaherty KT, Sondak VK: Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients. Ann Surg Oncol 2014, 21:1075-1081.
31. Gershenwald JE, Ross MI: Sentinel lymph node biopsy for cutaneous melanoma. N Eng J Med 2011, 364:1738-1745.
32. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK: Multivariate analysis of prognostic factors among 2, 313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452-2459.
33. Gershenwald JE, Soong SJ, Balch CM: 2010 TNM Staging System for Cutaneous Melanoma and Beyond. Ann Surg Oncol 2010, 17:1475-1477.
34. Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z: Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance. Mol Cancer Ther 2014, 13:1918-1928.
35. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012, 44:1006-1014.
36. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, et al: A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
37. Davis MJ, Ha BH, Holman EC, Halaban R, Schlessinger J, Boggon TJ: RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc Natl Acad Sci U S A 2013, 110:912-917.
38. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Dscov 2013, 3:350-362.
39. Hammond D, Zeng K, Espert A, Bastos RN, Baron RD, Gruneberg U, Barr FA: Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage due to dysregulated Aurora-A. J Cell Sci 2013, 126:3429-3440.
40. Dummer R, Robert C, Nyakas M, McArthur GA, Kudchadkar RR, Gomez-Roca C, Sullivan RJ, Flaherty K, Murer C, Michel D, Tang Z, De Parseval LA, Delord JP: Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma [abstract]. J Clin Oncol 2013, 31(suppl). abstr 9028.
41. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
42. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
43. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
44. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
45. Seghers AC, Wilgenhof S, Lebbé C, Neyns B: Successful rechallenge in two patients with BRAF V600E mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 2012, 22:466-472.
46. Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG: Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res 2014, 74:1067-1078.
47. Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A: Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer 2014, 13:83.
48. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012, 18:2502-2514.
49. Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH: A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res 2011, 17:6313-6321.
50. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011, 4:16.
51. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J: Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013, 368:1365-1366.
52. Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber TG, West BL, Bollag G, Ribas A: Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014, 74:153-161.
53. Del Gaizo MV: BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 2013, 332:202-205.
54. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745.
55. Bedikian AY, Lebbé C, Robert C, Agarwala SS, Cousin T, Wu J, Garbe C, Grob JJ: Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA) [abstract]. J Clin Oncol 2011, 29(suppl). abstr 8531.
56. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008, 26:5198-5203.
57. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R: A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011, 29:161-166.
58. Senft D, Berking C, Graf SA, Kammerbauer C, Ruzicka T, Besch R: Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS One 2012, 7:e30821.
59. Frederick DT, Salas Fragomeni RA, Schalck A, Neira IF, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MD, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ: Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers rationale for targeting de novo resistance using BH3 mimetics. PloS One 2014, 9:e101286.
60. Wroblewski D, Mijatov B, Mohana-Kumaran N, Lai F, Gallagher SJ, Haass NK, Zhang XD, Hersey P: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis 2013, 34:237-247.
61. Sale MJ, Cook SJ: That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol 2013, 169:1708-1722.
62. Ollila DW: Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 2006, 7:919-924.
63. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL: Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004, 139:961-966.
64. Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG: Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 2007, 14:2847-2853.
65. Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, Hoekstra HJ, Thompson JF: Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008, 15:1476-1484.
66. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26:527-534.
67. Hsueh EC, Gupta RK, Yee R, Leopoldo ZC, Qi K, Morton DL: Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol 2000, 7:232.
68. Coley W: The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. New York: Lea Brothers & Co; 1893.
69. Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB: Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 2012, 35:716-720.
70. Caracò C, Mozzillo N, Marone U, Simeone E, Benedetto L, Di Monta G, Di Cecilia ML, Botti G, Ascierto PA: Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer 2013, 13:564.
71. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
72. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS: Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014, 4:80-93.
73. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U: Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012, 30:3810-3818.
74. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM: Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012, 30:322-328.
75. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM: Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014, 9:e87705.
76. Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Ribas A, Kirkwood JM, Sondak VK: Phase III trial of high dose IFNa2-b versus cisplatin vinblastine, DTIC plus IL-2 and IFN in patients with high risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG and SWOG [abstract]. J Clin Oncol 2012, 30(suppl). abstr 8504.
77. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, McCarthy JB, DeLeo AB, Ferrone S: CSPG4 in cancer: multiple roles. Curr Mol Med 2010, 10:419-429.
78. Bukur J, Jasinski S, Seliger B: The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 2012, 22:350-358.
79. Meissner M, Whiteside TL, van Kuik-Romein P, Valesky EM, van den Elsen PJ, Kaufmann R, Seliger B: Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation. Br J Dermatol 2008, 158:930-940.
80. Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B: Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res 2011, 17:2668-2678.
81. Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fujii H, Seliger B, Kiessling R, Kono K: The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol 2013, 191:6261-6272.
82. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B: Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem 2010, 285:30419-30426.
83. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
84. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC: TIM3 + FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013, 2:e23849.
85. Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I: The HIF-1a hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2012, 2:608-623.
86. Martinez-Forero I, Azpilikueta A, Bolaños-Mateo E, Nistal-Villan E, Palazon A, Teijeira A, Perez-Chacon G, Morales-Kastresana A, Murillo O, Jure-Kunkel M, Zapata JM, Melero I: T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J Immunol 2013, 190:6694-6706.
87. Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I: Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013, 19:6151-6162.
88. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009, 21:233-240.
89. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter: Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013, 19:4792-4800.
90. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924.
91. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, et al: Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013, 36:133-151.
92. Kochenderfer JN, Rosenberg SA: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013, 10:267-276.
93. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP: A human memory T cell subset with stem celllike properties. Nat Med 2011, 17:1290-1297.
94. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, Di Piro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D: Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014, 2:632-642.
95. Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL Jr, Lee PP, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM: Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest 2014, 124:2147-2159.
96. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martín J, Altshuler D, Behrens TW, Alarcón-Riquelme ME: A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006, 38:550-555.
97. Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM: IRF5 gene polymorphisms in melanoma. J Transl Med 2012, 10:170.
98. Lida N, Dzutsev A, Stewart CA C, Bouladoux N, Smith L, Salcedo R, Cardone M, Back T, Kiu H, Cramer S, Naik S, Patri A, Wang E, Marincola FM, Belkaid Y, Trinchieri G, Goldszmid RS: Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013, 342:967-970.
99. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
100. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
101. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, Spigel D, Mokatrin A, Fine G, Gettinger S: Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer 2013, 49(suppl2). abstract 3408.
102. Suciu S, Ives N, Eggermont AM, Kirkwood JM, Lorigan P, Markovic S, Garbe C, Wheatley K: Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7, 500 melanoma patients (pts) [abstract]. J Clin Oncol 2014, 32(Suppl). 9067 abstract.
103. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF: Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006, 55:1185-1197.
104. Gajewski TF, Schreiber H, Fu YX: Innate and adaptive immune cells in the tumor microenviroment. Nat Immunol 2013, 14:1014-1022.
105. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013, 5:200ra116.
106. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
107. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF: Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 (+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014, 2:3.
108. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF: Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8[alpha] + dendritic cells. J Exp Med 2011, 208:2005-2016.
109. Chen G, Davies MA: Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. Hematol Oncol Clin North Am 2014, 28:523-536.
110. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C: Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013, 24:2174-2180.
111. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
112. Ribas A, Wolchok JD: Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol 2013, 25:291-296.
113. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
114. Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Görgens A, Giebel B, Schadendorf D, Paschen A: Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013, 133:1653-1663.
115. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
116. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA: BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19:1225-1231.
117. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P: BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012, 18:2326-2335.
118. Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol 2014, 25:747-753.
119. Puzanov I, Linette GP, Patel SP, Luke JJ, Sosman JA, Wolchok JD, Hamid O, Minor DR, Orford KW, Hug BA, Ma B, Matthys GM, Hoos A: Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Clin Oncol 2014, 32(suppl). 5s, abstr 2511.
120. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N: Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 2009, 106:20429-20434.
121. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA: The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 2013, 11:54.
122. Frishberg DP, Balch C, Balzer BL, Crowson AN, Didolkar M, McNiff JM, Perry RR, Prieto VG, Rao P, Smith MT, Smoller BR, Wick MR: Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 2009, 133:1560-1567.
123. Fortina P, Surrey S: Digital mRNA profiling. Nat Biotechnol 2008, 26:293-294.
124. Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, et al: Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II-III Resectable Disease. J Invest Dermatol 2014, 134:2202-2211.